长链非编码RNACASC9在结直肠癌组织中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.02.006

Abstract

Abstract: OBJECTIVE： To investigate expressions of long-chain noncoding RNA cancer susceptibility candidate 9 (lncRNA CASC9) in colorectal cancers and its relationships with clinical prognosis. METHODS： Eighty-seven cancer and adjacent tissues from patients with colorectal cancers were collected. Real time quantitative PCR was used to detect the expression levels of lncRNA CASC9 in the tissues. Relationships between the expression levels clinicopathological indicators were analyzed. Kaplan-meier survival analysis was performed，and log-rank method was used to test the relationship between the expression levels and clinical prognosis. RESULTS：The expression levels of lncRNA CASC9 in colorectal cancer were significantly higher than that in adjacent tissues (P<0.01) and were significantly correlated with different degrees of differentiation (χ²=6.877， P=0.032)， TNM stage (χ²=7.660， P=0.022) and lymph node metastasis (χ²=9.901， P=0.002)， but not with gender，age，tumor diameter and tumor locations (All P>0.05). Kaplan Meier survival analyses show that the overall survival and progression- free survival times among patients with high expression of lncRNA CASC9 were significantly shorter than those with low expression (χ²=17.91， P<0.01； χ²=11.23， P=0.001). CONCLUSION：lncRNA CASC9 was highly expressed in colorectal cancers and was related to the degree of differentiation，TNM stage and lymph node metastasis of the cancers. It may be useful as a diagnostic marker of colorectal cancers.

Key words: colorectal cancer, long chain noncoding RNA, cancer susceptibility candidate 9, prognosis

CLC Number:

R735.3

LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun. Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 110-113.

References

[1] THANIKACHALAM K, KHAN G. Colorectal cancer and nutrition[J]. Nutrients, 2019, 11(1): 164.
[2] DEKKER E, TANIS P J, VLEUGELS J L A, et al. Colorectal cancer[J]. Lancet, 2019, 394(10207): 1467-1480.
[3] ZHOU B, YANG H, YANG C, et al. Translation of noncoding RNAs and cancer[J]. Cancer Lett, 2021, 497: 89-99.
[4] NANDWANI A, RATHORE S, DATTA M. LncRNAs in cancer: regulatory and therapeutic implications[J]. Cancer Lett, 2021, 501: 162-171.
[5] IACCARINO I, KLAPPER W. LncRNA as cancer biomarkers [J]. Methods Mol Biol, 2021, 2348: 27-41.
[6] ZHANG Y L, LIU Q F, LIAO Q. Long noncoding RNA: a dazzling dancer in tumor immune microenvironment[J]. J Exp Clin Cancer Res, 2020, 39(1): 231.
[7] CHEN S A, SHEN X. Long noncoding RNAs: functions and mechanisms in colon cancer[J]. Mol Cancer, 2020, 19(1): 167.
[8] QI Y Y, SONG C Y, ZHANG J L, et al. Oncogenic LncRNA CASC₉ in cancer progression[J]. Curr Pharm Des, 2021, 27(4): 575-582.
[9] BING Z X, HAN J S, ZHENG Z B, et al. FOXO₃^- induced oncogenic lncRNA CASC₉ enhances gefitinib resistance of non-small-cell lung cancer through feedback loop[J]. Life Sci, 2021, 287: 120012.
[10] 梁峰, 张玮, 王胜杰, 等. 干扰CASC9表达对结直肠癌细胞增殖、凋亡的影响及其与miR-195-5p/CCND1轴的关系[J]. 山东医药, 2021, 61(26): 1-5.
[11] ZHANG Y X, CHANG J Z, JIANG W W, et al. Long non-coding RNA CASC₉/microRNA-590-3p axis participates inlutein-mediated suppression of breast cancer cell proliferation [J]. Oncol Lett, 2021, 22(1): 544.
[12] LIU J, MAYEKAR M K, WU W, et al. Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G[J]. Cancer Lett, 2020, 493: 217-227.
[13] SHAO G L, WANG M C, FAN X L, et al. lncRNA CASC₉ positively regulates CHK₁ to promote breast cancer cell proliferation and survival through sponging the miR-195/497 cluster[J]. Int J Oncol, 2019, 54(5): 1665-1675.
[14] GAO G D, LIU X Y, LIN Y, et al. LncRNA CASC₉ promotes tumorigenesis by affecting EMT and predicts poor prognosis in esophageal squamous cell cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2): 422-429.
[15] YANG Y X, CHEN D, LIU H, et al. Increased expression of lncRNA CASC₉ promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma[J]. Cell Death Dis, 2019, 10 (2): 41.
[16] WU Y Y, HU L W, LIANG Y, et al. Up-regulation of lncRNA CASC₉ promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2[J]. Mol Cancer, 2017, 16(1): 150.
[17] ZHAN Y H, ZHANG L H, YU S B, et al. Long non- coding RNA CASC₉ promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer[J]. J Exp Clin Cancer Res, 2020, 39(1): 136.
[18] ZHAO W G, CHEN T B, ZHAO Y H. Upregulated lncRNA CASC₉ contributes to progression of non-small cell lung cancer through inhibition of miR-335-3p and activation S100A14 expression[J]. Onco Targets Ther, 2020, 13(11): 6027-6036.

Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[2]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[3]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[4]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[5]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[6]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[7]	LI Bo, LI Gairui, ZHAO Wei, PENG Xiaolin, ZHAO Dan, PENG Ji. Evaluation of sample preservation solution for fecal DNA detection [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 312-316.
[8]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[9]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[10]	DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.
[11]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.
[12]	SHAO Junguo, JIAO Wenjing, WANG Xuexiao, ZHANG Jinyan, MA Ming. Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 369-373.
[13]	Lü Yanping, WU Chuancheng, YANG Shuangfeng, HE Chenzhou, HAN Renjie, YAN Wei, LIU Baoying. Relationship between differentially expressed miRNA-SNPs and prognosis of gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 380-386.
[14]	GUO Xiujuan, DU Yanyan, YAN Xi, ZHAO Xuetao, HAN Lina, WU Yipeng, WANG Xuexiao, MA Ming. Expression and clinical significance of CREB in esophageal squamous cell carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 387-390,394.
[15]	ZHU Yiqing, ZHANG Tongtong, ZHENG Junwen, HAO Jiajie, CAI Yan, WANG Mingrong, LIANG Jianwei, ZHANG Yu. Expression status of p-mTOR and its prognostic implication in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 161-165.